In another study where single-cell characterization was done before and during treatment for a breast cancer patient, while CTCs revealed distinct mutational profiles at different time points, all CTCs harbored mutation in the HER2 gene (p.V777L), regardless of sampling time, indicating resistance to HER2-targeted treatment in this patient. The gene discussed is ERBB2; the disease is breast cancer.